Xcout Intel
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Subscribe to see Tenaya Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tenaya Therapeutics, Inc. at a glance
Tenaya Therapeutics, Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (TNYA) with a market capitalisation of $130.1M. Xcout tracks 28 named people at Tenaya Therapeutics, Inc., including Faraz Ali (President, CEO & Director).
Tenaya Therapeutics, Inc. leadership
- Faraz AliPresident, CEO & Director
- Eric HyllengrenCFO & Principal Accounting Officer
- Kee-Hong KimChief Technology Officer
- Whittemore G. TingleyChief Medical Officer
- Whit TingleyChief Medical Officer
- Jennifer DrimmerGeneral Counsel
22 more named people on record for Tenaya Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Tenaya Therapeutics, Inc. competitors
A few of Tenaya Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
SonoThera, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on developing genetic medicines and advancing the field of gene therapy.
Scribe Therapeutics is a clinical-stage biotechnology company that develops genetic therapies for conditions such as heart disease and has pursued public offerings in the United States.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Get Tenaya Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Tenaya Therapeutics, Inc. in Xcout Intel
- 28 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access